Stockreport

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need...

PDS Biotechnology Corporation  (PDSB) 
Last pds biotechnology corporation earnings: 11/7 06:00 am Check Earnings Report
PDF First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemothe [Read more]